Company Description
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases.
Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis.
The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate.
It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product.
The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019.
Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Feb 8, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 130 |
| CEO | Warner Biddle |
Contact Details
Address: 5980 Horton Street, Suite 550 Emeryville, California 94608 United States | |
| Phone | 510 925 2492 |
| Website | kyvernatx.com |
Stock Details
| Ticker Symbol | KYTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $22.00 |
| CIK Code | 0001994702 |
| CUSIP Number | 501976104 |
| ISIN Number | US5019761049 |
| Employer ID | 83-1365441 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Warner Biddle | Chief Executive Officer and Director |
| Christi L. Shaw | Executive Chairperson |
| Dr. Marc Grasso M.D. | Chief Financial Officer |
| Dr. Naji H. Gehchan M.B.A., M.D. | Chief Medical and Development Officer |
| Dr. Tom Van Blarcom Ph.D. | Senior Vice President and Head of Research |
| Mayo Pujols | Chief Technology Officer |
| Jessica Serra | Head of Investor Relations |
| Tracy Rossin | Senior Vice President of Corporate Affairs and Communications and Investor Relations |
| Cara Bauer Ph.D. | Chief Human Resources Officer |
| Dan Maziasz | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2026 | 8-K | Current Report |
| Apr 22, 2026 | 8-K | Current Report |
| Apr 20, 2026 | 8-K | Current Report |
| Apr 17, 2026 | 144 | Filing |
| Apr 14, 2026 | 144 | Filing |
| Apr 13, 2026 | ARS | Filing |
| Apr 13, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 13, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 7, 2026 | 144 | Filing |
| Apr 2, 2026 | EFFECT | Notice of Effectiveness |